Transfemoral transcatheter aortic valve replacement was associated with a significantly lower rate of postoperative in-hospital death (OR 0.67) compared to the transapical approach.
Meta-Analysis (n=19,520)
Does transfemoral transcatheter aortic valve replacement reduce mortality and morbidity compared to the transapical approach in patients with aortic disease?
Transfemoral TAVR is associated with lower early mortality, bleeding, and acute kidney injury compared to the transapical approach, supporting its use as the preferred access route despite higher vascular and pacemaker risks.
Estimación del efecto: OR 0.67 (95% CI 0.59-0.77)
valor p: p=<0.001
Abstract Background Transcatheter aortic valve replacement (TAVR) has gained increasing acceptance for patients with aortic disease. Both transfemoral (TF-TAVR) and transapical (TA-TAVR) approach were widely adopted while their performances are limited to a few studies with controversial results. This meta-analysis aimed to compare the mortality and morbidity of complications between TF- versus TA-TAVR based on the latest data. Methods Electronic databases were searched until April 2021. RCTs and observational studies comparing the outcomes between TF-TAVR versus TA-TAVR patients were included. Heterogeneity assumption was assessed by an I 2 test. The pooled odds ratios(OR) or mean differences with corresponding 95% confidence intervals (CI) were used to evaluate the difference for each end point using a fixed-effect model or random-effect model based on I 2 test. Results The meta-analysis included 1 RCT and 20 observational studies, enrolling 19,520 patients (TF-TAVR, n = 11,986 and TA-TAVR, n = 7,534). Compared with TA-TAVR, TF-TAVR patients showed significantly lower rate of postoperative in-hospital death (OR = 0.67, 95% CI 0.59–0.77, P < 0.001) and 1-year death (OR = 0.53, 95% CI 0.41–0.69, P < 0.001). Incidence of major bleeding and acute kidney injury were lower and length of hospital stay was shorter, whereas those of permanent pacemaker and major vascular complication were higher in TF-TAVR patients. There were no significant differences between TF-TAVR versus TA-TAVR for stroke and mid-term mortality. Conclusions There were fewer early deaths in patients with transfemoral approach, whereas the number of mid-term deaths and stroke was not significantly different between two approaches. TF-TAVR was associated with lower risk of bleeding, acute kidney injury as well as shorter in-hospital stay, but higher incidence of vascular complication and permanent pacemaker implantation.
Guo et al. (Wed,) conducted a meta-analysis in Aortic disease (n=19,520). Transfemoral transcatheter aortic valve replacement (TF-TAVR) vs. Transapical transcatheter aortic valve replacement (TA-TAVR) was evaluated on Postoperative in-hospital mortality (OR 0.67, 95% CI 0.59-0.77, p=<0.001). Transfemoral transcatheter aortic valve replacement was associated with a significantly lower rate of postoperative in-hospital death (OR 0.67) compared to the transapical approach.